NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials, has announced their...
LONDON, Feb. 13, 2025 /PRNewswire/ -- Precision Cardiovascular (PCV), an innovator in next-generation cardiac health solutions, today announced the appointment...
Original research article published by Frontiers, a top peer-reviewed scientific journal WASHINGTON, Feb. 13, 2025 /PRNewswire/ -- Otolith Labs, a...
– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia...
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are...
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint...
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 –...
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with...
NEW YORK, Feb. 12, 2025 /PRNewswire/ -- Aetion, the global leader in real-world evidence (RWE) technology and analytics, has been...
Gold-standard accreditation underscores Emmes Group's commitment to secure and data-rich trials for biotech and pharma partners ROCKVILLE, Md., Feb. 12,...
Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan. CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/...
New market position highlights Clearsense as a leading healthcare data enablement platform, showcasing the transformative value of its solutions NASHVILLE,...
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million...
Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex...
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal...